In 2023, demand for GLP-1 receptor agonists such as Lilly’s tirzepatitde and Novo Nordisk’s semaglutide surged just as demand for COVID-19 therapies waned. As a result, Novo Nordisk had 33% growth at constant exchange rates over the first nine months of the year. Similarly, Lilly experienced a 37% jump in revenue in the third quarter,…